张唐娟, 李印, 韩渭丽, 王海玲, 江涛, 任景丽, 杨建学, 郭海周, 孟辉, 鲁建亮, 陈曦, 付文婷 王立东. 529 例食管原发小细胞癌临床流行病学特征及治疗和预后分析*[J]. 中国肿瘤临床, 2016, 43(13): 571-576. DOI: 10.3969/j.issn.1000-8179.2016.13.258
引用本文: 张唐娟, 李印, 韩渭丽, 王海玲, 江涛, 任景丽, 杨建学, 郭海周, 孟辉, 鲁建亮, 陈曦, 付文婷 王立东. 529 例食管原发小细胞癌临床流行病学特征及治疗和预后分析*[J]. 中国肿瘤临床, 2016, 43(13): 571-576. DOI: 10.3969/j.issn.1000-8179.2016.13.258
Tangjuan ZHANG, Yin LI, Weili HAN, Hailing WANG, Tao JIANG, Jingli REN, Jianxue YANG, Haizhou GUO, Hui MENG, Hui Meng, Jianliang LU, Xi CHEN. Analysis of the clinical and epidemiological changes, treatments, and prognoses of primary esophageal small cell carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(13): 571-576. DOI: 10.3969/j.issn.1000-8179.2016.13.258
Citation: Tangjuan ZHANG, Yin LI, Weili HAN, Hailing WANG, Tao JIANG, Jingli REN, Jianxue YANG, Haizhou GUO, Hui MENG, Hui Meng, Jianliang LU, Xi CHEN. Analysis of the clinical and epidemiological changes, treatments, and prognoses of primary esophageal small cell carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(13): 571-576. DOI: 10.3969/j.issn.1000-8179.2016.13.258

529 例食管原发小细胞癌临床流行病学特征及治疗和预后分析*

Analysis of the clinical and epidemiological changes, treatments, and prognoses of primary esophageal small cell carcinoma

  • 摘要: 目的:探讨食管原发小细胞癌(primar yesophageal small cell carcinoma ,PESC)临床流行病学特征及生存影响因素。方法:回顾性分析1992年至2015年529 例来自郑州大学第一附属医院河南省食管癌重点开放实验室500 000 例食管癌及贲门癌临床信息数据库PESC患者临床流行病学资料,其中241 例患者纳入生存分析。采用Kaplan-Meier 法计算5 年生存率,应用Log-rank 法检验比较各组间生存差异。结果:529 例PESC入组分析,占同期食管恶性肿瘤0.2%(529/ 251 707),其发生率逐年增长(R2= 0.574)。241 例PESC总体1、2、3 及5 年的生存率分别为55% 、40% 、29% 及9% ,中位生存期为21.9 个月。根据小细胞肺癌VALSG分期标准,局限期和广泛期患者中位生存分别为24.3 个月和17.5 个月,差异具有统计学意义(P = 0.003)。 PESC患者不同治疗方式生存期存在显著差异(P = 0.004),其中手术联合放化疗的患者中位生存期28.8 个月优于单纯化疗组17.8 个月(P = 0.015)及放疗+ 化疗组患者14.5 个月(P = 0.004);局限期以手术治疗为主的患者中位生存期27.7 个月,与非手术患者16.2 个月,差异具有统计学意义(P = 0.007)。 此外,PESC术前活检病理确诊率为40.8% 。结论:PESC是一种较为罕见的食管恶性肿瘤,发生率呈上升趋势,其术前确诊率较低,预后极差,以手术为主的综合治疗有助于延长其短期生存期。

     

    Abstract: Objective:To characterize the clinical and epidemiological changes, treatments, and prognoses of primary esophageal small cell carcinoma (PESC). Methods:A retrospective analysis was conducted using the clinical epidemiology data of529 PESC patients se -lected from the clinical databases of 500 ,000 esophageal and gastric cardiac carcinomas of the Henan Key Laboratory for Esophageal Cancer Research (1992- 2015). Among these patients, 241 cases were included in the survival analysis. The five-year survival rate was calculated using Kaplan- Meier analysis, and the differences in survival rates were compared using the Log- rank analysis model. Re-sults: All529 PESC cases were analyzed, which accounted for 0. 2% of esophageal cancers diagnosed in the same period. The incidence of PESC increased annually (R2=0. 574 ). The survival rates for 1-, 2-, 3-, and 5- year of 241 PESC patients were 55%, 40%, 29%, and 9%, respectively, and the median survival time was 21. 9 months. On the basis of the VALSG criteria of lung small cell carcinoma, a statisti-cal difference was observed in the overall survival rates for limited and extensive diseases (P=0. 003 ), with the median survival time of 24. 3 and 17. 5 months, respectively. Furthermore, significant differences were observed on survival with various treatment modalities (P=0. 004 ). The median survival time of PESC patients treated with combined surgery and radiochemotherapies (28. 8 months) was lon-ger than those with either chemotherapy (17. 8 months,P=0. 015 ) or chemoradiotherapy (14. 5 months,P=0. 004 ). In limited disease pa-tients, the median survival time was longer in patients treated with surgery (27. 7 months) than in those without surgery (16. 2 months, P=0. 007 ). Notably, the biopsy diagnosis before surgery for PESC was only 40. 8%.Conclusion: PESC is a rare malignant carcinoma with increasing incidence. PESC presents poor prognosis, and the survival rate can be improved through combined therapies based on sur -gery. A high misdiagnosis rate for PESC is observed before surgery with biopsy.

     

/

返回文章
返回